180 related articles for article (PubMed ID: 26461817)
1. Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100.
Manalo IF; Gilbert KE; Wu JJ
J Drugs Dermatol; 2015 Oct; 14(10):1086-8. PubMed ID: 26461817
[No Abstract] [Full Text] [Related]
2. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
[No Abstract] [Full Text] [Related]
3. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis: the future.
Menter MA; Griffiths CE
Dermatol Clin; 2015 Jan; 33(1):161-6. PubMed ID: 25412790
[TBL] [Abstract][Full Text] [Related]
6. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed.
Kimmel G; Chima M; Kim HJ; Bares J; Yao CJ; Singer G; Kim SJ; Bagel J; Lebwohl M
J Am Acad Dermatol; 2019 Sep; 81(3):857-859. PubMed ID: 31078609
[No Abstract] [Full Text] [Related]
7. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
Kimura R; Sugita K; Yamamoto O
Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
[No Abstract] [Full Text] [Related]
8. Safety of secukinumab in the treatment of psoriasis.
Blauvelt A
Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
[TBL] [Abstract][Full Text] [Related]
9. Broadalumab (Siliq)--another IL-17A antagonist for psoriasis.
Med Lett Drugs Ther; 2017 Jul; 59(1525):118-119. PubMed ID: 28699932
[No Abstract] [Full Text] [Related]
10. Two Minimal Clinically Important Difference (2MCID): A New Twist on an Old Concept.
Ali FM; Salek MS; Finlay AY
Acta Derm Venereol; 2018 Jul; 98(7):715-717. PubMed ID: 29362815
[No Abstract] [Full Text] [Related]
11. Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis.
Romiti R; Valenzuela F; Chouela EN; Xu W; Pangallo B; Moriarty SR; Gürbüz S; Riedl E
Br J Dermatol; 2019 Jul; 181(1):202-203. PubMed ID: 30609008
[No Abstract] [Full Text] [Related]
12. Depression? It's the Disease NOT the Drug.
Kircik LH
J Drugs Dermatol; 2018 Aug; 17(8):s28. PubMed ID: 30124736
[TBL] [Abstract][Full Text] [Related]
13. Anti IL-17 flared psoriasis in a patient on secukinumab.
Noell C; McQuade B; Gottlieb A; Rosmarin D
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28547879
[No Abstract] [Full Text] [Related]
14. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies.
Campa M; Menter A
Expert Opin Investig Drugs; 2016 Nov; 25(11):1337-1344. PubMed ID: 27687859
[TBL] [Abstract][Full Text] [Related]
15. Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab.
Smith SD; Conrad C; Ramharter M; Gottlieb AB; Patel H; Xu W; Riedl E; Schuster C
J Am Acad Dermatol; 2020 Jul; 83(1):261-263. PubMed ID: 32092375
[No Abstract] [Full Text] [Related]
16. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis drug discovery: methods for evaluation of potential drug candidates.
Svensson L; Røpke MA; Norsgaard H
Expert Opin Drug Discov; 2012 Jan; 7(1):49-61. PubMed ID: 22468893
[TBL] [Abstract][Full Text] [Related]
18. Therapeutics: Silencing psoriasis.
Crow JM
Nature; 2012 Dec; 492(7429):S58-9. PubMed ID: 23254974
[No Abstract] [Full Text] [Related]
19. Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors.
Oiwa T; Honda T; Otsuka A; Kabashima K
J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):e122-e123. PubMed ID: 28983980
[No Abstract] [Full Text] [Related]
20. Peripheral lymph node recurrence of tuberculosis after ustekinumab treatment.
Sánchez-Moya AI; Daudén E
Arch Dermatol; 2012 Nov; 148(11):1332-3. PubMed ID: 23165852
[No Abstract] [Full Text] [Related]
[Next] [New Search]
